Stockscreener 앱 받기
7.21
0.08%
-0.0055
시간 외 거래:
7.21
전일 마감가:
$7.2155
열려 있는:
$7.189
하루 거래량:
3,113
Relative Volume:
0.12
시가총액:
$20.12M
수익:
$6.56M
순이익/손실:
$-14.92M
주가수익비율:
-13.35
EPS:
-0.54
순현금흐름:
$-33.87M
1주 성능:
-5.01%
1개월 성능:
-15.28%
6개월 성능:
+28.64%
1년 성능:
+0.00%
1일 변동 폭
$7.189
$7.341
1주일 범위
$7.15
$7.70
52주 변동 폭
$3.34
$16.50
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
SLGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
7.21 | 21.14M | 6.56M | -14.92M | -33.87M | -0.54 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2019-12-31 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-31 | 재확인 | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd 주식(SLGL)의 최신 뉴스
Sol-Gel Technologies (NASDAQ:SLGL) Shares Down 0.1% – What’s Next? - Defense World
Sol-Gel (SLGL) Projects Cash Resources to Sustain Through Q1 202 - GuruFocus
Sol-Gel Technologies Reports Q1 2025 Financial Results - TipRanks
Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic By Stocktwits - Investing.com India
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SLGL Boosts Q1 Revenue to $1 Million, Doubling Last Year's Perfo - GuruFocus
Sol-Gel (SLGL) Projects Cash Resources to Sustain Through Q1 2027 | SLGL Stock News - GuruFocus
Sol-Gel Reports First Quarter 2025 Results - Stock Titan
Sol-Gel Reports First Quarter 2025 Results | SLGL Stock News - GuruFocus
Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses - Nasdaq
Actinic Keratosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Medication, Therapies, NICE Approvals and Companies by DelveInsight - The Globe and Mail
Sol-Gel Technologies Regains Nasdaq Compliance - TipRanks
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com
SEC Form 424B3 filed by Sol-Gel Technologies Ltd. - Quantisnow
Will Sol-Gel Deliver The First Preventive Treatment For Gorlin Syndrome? - RTTNews
Sol-Gel Technologies (NASDAQ:SLGL) Stock Price Down 39.5% – Should You Sell? - Defense World
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference - Barchart.com
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Sol-Gel Technologies Announces Reverse Share Split to Regain Nasdaq Compliance - TipRanks
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA - Barchart.com
Insider Buys Additional US$98k In Sol-Gel Technologies Stock - simplywall.st
Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares - Yahoo Finance
This Sol-Gel Technologies Insider Increased Their Holding In The Last Year - Yahoo Finance
Sol-Gel Technologies announces 10-for-1 reverse stock split By Investing.com - Investing.com Nigeria
Sol-Gel Technologies (SLGL) Announces 10-for-1 Reverse Stock Spl - GuruFocus
Sol-Gel Technologies announces 10-for-1 reverse stock split - Investing.com
Sol-Gel Announces Reverse Share Split - TradingView
Basal Cell Nevus Syndrome Treatment Market 2032: EMA, PDMA, FDA - openPR.com
Sol-Gel Technologies Ltd [SLGL] Investment Guide: What You Need to Know - knoxdaily.com
Did Sol-Gel Technologies Ltd (SLGL) perform well in the last session? - uspostnews.com
Sol-Gel secures $16 million, extends cash runway By Investing.com - Investing.com Canada
Sol-Gel Technologies Secures $16 Million Deal with Mayne Pharma for U.S. Rights to EPSOLAY and TWYNEO - TipRanks
Sol-Gel secures $16 million, extends cash runway - Investing.com Australia
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - The Manila Times
Sol-Gel's Strategic Pivot: $16M Product Sale Funds Promising Cancer Drug Development - Stock Titan
(PDF) Synthesis of Magnesium Oxide Nanoparticles by Sol-Gel Process - ResearchGate
XBiotech Inc. (NASDAQ:XBIT) Shares Sold by American Century Companies Inc. - Defense World
Raymond James Financial Inc. Invests $101,000 in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) - Defense World
Raymond James Financial Inc. Purchases New Shares in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World
American Century Companies Inc. Sells 20,635 Shares of AxoGen, Inc. (NASDAQ:AXGN) - Defense World
Sol-Gel Technologies Ltd. (4SG.F) latest stock news and headlines - Yahoo
Investors Don't See Light At End Of Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Tunnel And Push Stock Down 31% - simplywall.st
(PDF) Synthesis and Characterization of CZTS Thin Films by Sol-Gel Method without Sulfurization - ResearchGate
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal - TipRanks
(PDF) NaFePO4 Particles as a Cathode of Sodium Ion-Battery via Sol-Gel Method: A Review on Synthesis - ResearchGate
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Sol Gel Technologies Ltd expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Retinoic Acid Receptor Alpha Market Unlocking Growth Opportunities Through Smart Solutions - expressvartha.in
Sol Gel Technologies Ltd (SLGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):